文献速递流行病学与生物统计真实世界研究与卫生经济

合并症与癌症临床试验讨论及参与相关:健康信息全国趋势调查-监测、流行病学和最终结果项目(2021年)发现

Comorbidities were associated with cancer clinical trial discussion and participation: findings from the Health Information National Trends Survey-Surveillance, Epidemiology, and End Results Program (2021).
PubMed 文献 · J Clin Epidemiol · 2023-09-30

研究纳入958名癌症幸存者,分析合并症与临床试验讨论或实际参与的关系。75%患者有至少一种合并症,仅15%报告试验讨论、8%报告参与。有合并症与试验讨论率较低显著相关(未调整OR=0.46,P=0.001;调整后OR=0.54,P=0.02)。

要点

  • 958名癌症幸存者中75%有至少一种合并症,常见高血压(56%)和糖尿病(26%)。
  • 仅15%报告医疗团队讨论过临床试验,8%报告实际参与试验。
  • 有合并症者试验讨论率较低:未调整22.9% vs 12.1%(OR=0.46,P=0.001),调整后20.5% vs 12.8%(aOR=0.54,P=0.02)。

核心结论

  • 有合并症的癌症患者临床试验讨论率较低,提示试验参与者可能缺乏代表性。

研究设计与样本

  • 研究纳入健康信息全国趋势调查-监测、流行病学和最终结果项目(2021年)的958名癌症幸存者,采用基于设计的逻辑回归分析。

主要发现

  • 75%患者有至少一种合并症,常见高血压(56%)和糖尿病(26%)。
  • 仅15%参与者报告试验讨论,8%报告试验参与。
  • 有至少一种合并症与试验讨论率较低显著相关:未调整分析22.9% vs 12.1%(OR=0.46,P=0.001),调整后分析20.5% vs 12.8%(aOR=0.54,P=0.02)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Oncology clinical trials are recommended to better reflect real-world cancer patient populations and to increase patient access to new treatments in trials. The influence of comorbidities on trial participation is unclear. This study examined the association of having comorbidities and patients' experiences with clinical trial discussion or actual participation. STUDY DESIGN AND SETTING: We included 958 cancer survivors from Health Information National Trends Survey-Surveillance, Epidemiology, and End Results Program. Trial discussion was defined as whether their medical team discussed cancer clinical trials, and trial participation was defined as whether they participated. Comorbidities included diabetes, hypertension, heart condition, chronic lung disease, and depression/anxiety disorder. Design-based logistic regression results were conducted. RESULTS: Seventy-five percent of patients had one or more comorbidities, commonly having hypertension (56%) and diabetes (26%). Only 15% of participants reported trial discussion and 8% reported trial participation. Having one or more comorbidities was significantly associated with lower rates of trial discussion in univariate analysis (22.9% vs. 12.1%, odds ratio = 0.46, P = 0.001), and such association was pertained in adjusted logistic regression (20.5% vs. 12.8%, adjusted odds ratio = 0.54, P = 0.02). CONCLUSION: Findings suggest patients with comorbidities were underrepresented in cancer clinical trials, implying a potential lack of representativeness among trial participants.

来源:J Clin Epidemiol,查看原文。版权归原作者所有。

引用

  1. Cho Y, Shang S, Zhou W, et al. Comorbidities were associated with cancer clinical trial discussion and participation: findings from the Health Information National Trends Survey-Surveillance, Epidemiology, and End Results Program (2021). J Clin Epidemiol. 2023. PMID: 37783400. doi:10.1016/j.jclinepi.2023.09.016

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。